Drug Transparency Bill Stripped of Critical Provisions Ahead of Senate Vote
4 hours ago
- The Clear Labels Act, which aimed to require drug labels to show the exact manufacturing location, has been weakened by removing a unique facility identifier and extending compliance to five years.
- Safety experts and former inspectors argue the changes undermine transparency, as addresses can be inconsistent and harder to trace than a unique ID number.
- Critics worry about a potential loophole allowing manufacturers to list a 'place of business' like a headquarters rather than the actual factory.
- Supporters of the bill cite national security and cost concerns as reasons for the revisions, but opponents say public health risks outweigh those concerns.